TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor TLE3 conferred resistance to AR antagonists apalutamide and enzalutamide. Genes differentially expressed upon TLE3 loss s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:eLife
Autors principals: Palit, Sander AL, Vis, Daniel, Stelloo, Suzan, Lieftink, Cor, Prekovic, Stefan, Bekers, Elise, Hofland, Ingrid, Šuštić, Tonći, Wolters, Liesanne, Beijersbergen, Roderick, Bergman, Andries M, Győrffy, Balázs, Wessels, Lodewyk FA, Zwart, Wilbert, van der Heijden, Michiel S
Format: Artigo
Idioma:Inglês
Publicat: eLife Sciences Publications, Ltd 2019
Matèries:
Cancer Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6968917/
https://ncbi.nlm.nih.gov/pubmed/31855178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.47430
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars